Online inquiry

IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ363MR)

This product GTTS-WQ363MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ALB&IL6R gene. The antibody can be applied in Inflammatory conditions, Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000477.7; NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 213; 3570
UniProt ID P02768; P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ363MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6172MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CP-751871
GTTS-WQ1433MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ACC-001
GTTS-WQ7140MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FG-3019
GTTS-WQ13338MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-06801591
GTTS-WQ5180MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CAT-354
GTTS-WQ15413MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA TSR-022
GTTS-WQ9070MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMC-A12
GTTS-WQ5310MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CD166 AADC
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW